Clinical TrialMay 14, 2026, 08:42 AM
AIM ImmunoTech Ampligen Improves Pancreatic Cancer OS by 7.2 Months
AI Summary
AIM ImmunoTech announced positive data from its Named Patient Program (NPP) and positive interim data from its ongoing Phase 2 DURIPANC clinical trial for Ampligen (rintatolimod) in late-stage pancreatic cancer. The NPP data showed significant improvements in Progression-Free Survival (PFS) and Overall Survival (OS) compared to historical controls. A Virtual Investor KOL Connect segment provided an in-depth discussion on Ampligen's progress and strategic focus for this lethal malignancy.
Key Highlights
- Ampligen NPP showed Overall Survival (OS) of 19.7 months vs 12.5 months for historical controls, an improvement of 7.2 months.
- Ampligen NPP showed Progression-Free Survival (PFS) of 12.6 months vs 8.6 months for historical controls, an improvement of 4 months.
- For patients with Neutrophil/Lymphocyte ratios less than 4.5, OS improved by 22.3 months to 34.8 months.
- For patients with CA 19-9 less than 1000, OS improved by 11.6 months to 24.1 months.
- Ongoing Phase 2 DURIPANC study (Ampligen with Imfinzi) expects Mid-Year 2026 report and enrollment completion in June 2026.
- Clinical experience in both the NPP and DURIPANC suggests consistent improvement in Quality of Life.